aprepitant + Placebo
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatitis
Conditions
Pancreatitis
Trial Timeline
Aug 1, 2007 → Nov 1, 2012
NCT ID
NCT00736073About aprepitant + Placebo
aprepitant + Placebo is a pre-clinical stage product being developed by Merck for Pancreatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00736073. Target conditions include Pancreatitis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00572572 | Phase 3 | Completed |
| NCT00736073 | Pre-clinical | Completed |
Competing Products
8 competing products in Pancreatitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CREON | AbbVie | Pre-clinical | 23 |
| Creon36™ | AbbVie | Phase 2 | 52 |
| Nexium (esomeprazole magnesium) + Placebo to Nexium + Viokase 16 (pancrelipase) + Nexium + Viokase 16 + placebo to Nexium | AstraZeneca | Phase 1 | 33 |
| Infusion of 5 mg/kg Infliximab + Infusion of 10 mg/kg Infliximab | Merck | Phase 2 | 52 |
| Meropenem | Pfizer | Approved | 84 |
| meropenem | Pfizer | Approved | 84 |
| Tanezumab | Pfizer | Phase 2 | 51 |
| RG1068 (synthetic human secretin) | Repligen | Phase 3 | 74 |